Long

Athira - Hold accumulate

Updated

Athira Pharma's explosive growth potential is attributed to its innovative therapies aimed at neurological disorders, such as Alzheimer’s, Parkinson’s disease dementia, and dementia with Lewy bodies. The flagship molecule, ATH-107 (also known as fosgonimeton or fosgo), currently in advanced clinical testing, targets the HGF/MET system to promote neuronal health and recovery. Phase 2 trials have yielded encouraging outcomes, with Phase 2/3 results anticipated in the latter half of 2024. Thomas Shrader, a sector expert, underscores fosgo’s potential in treating mild-to-moderate Alzheimer’s, positioning it as a pivotal monotherapy for patients at later stages of the disease. I am looking forward to a price pullback to the $2.50-$2.80 range, considering it an attractive entry point within the liquidity shelf, given the timeline for upcoming trial data. Shrader rates ATHA shares a Buy, and his $10 price target points toward an upside of 200% by the end of this year.

Trade active

Athira Pharma shared several updates today. They highlighted ongoing progress in their clinical trials and development programs for neurodegenerative diseases, including Alzheimer's and Parkinson's disease, as well as amyotrophic lateral sclerosis (ALS). They reported on the SHAPE Phase 2 clinical trial of fosgonimeton in Parkinson’s disease dementia and Dementia with Lewy bodies, noting encouraging results, although the primary endpoint was not met. The trial showed positive effects on cognitive measures with fosgonimeton treatment. Additionally, Athira discussed their next-generation drug candidate, ATH-1105, developed for ALS, supported by preclinical evidence demonstrating significant improvements in ALS animal models. They plan to initiate first-in-human studies of ATH-1105 in the first half of 2024.

Athira Pharma also updated on the LIFT-AD trial for Alzheimer's disease, focusing on a 40 mg dosing strategy, with patient enrollment completion expected in Q1 2024 and topline results anticipated in the second half of 2024. They mentioned that more than 85% of participants from completed trials have elected to enroll in the Open Label Extension (OLEX) study to receive up to 30 months of open-label treatment.

Furthermore, they've recently presented clinical and preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s and Parkinson’s diseases at the AD/PD™ 2024 International Conference. For more detailed information, you can visit Athira Pharma's website

Hit my buy target, not sure if this stock wants to trade lower. will leave some cash on the table to avg down.

Trade active

I don't see much fundamentally that lowers the value of this stock, Averaging down here and digging my feet in.

Trade active

Added Position

Trade active

I think MM's sent this down to fill that gap that was left on the way up, as they may have felt a need for price discovery, Remember not all gaps fill, and some can take years! gaps only fill if there is a need for price discovery!

Trade active

Bought More

SPYDERMARKET

Also on:

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.